Alnylam Pharmaceuticals, Inc.
DE ˙ XTRA ˙ US02043Q1076
251,80 € ↑6,70 (2,73%)
2026-06-03
DEL PRIS
SecurityDE:DUL / Alnylam Pharmaceuticals, Inc.
InstitutionUs Bancorp \de\
Latest Disclosed Ownership7,381 shares
Latest Disclosed Value $ 2,442,151
Us Bancorp \de\ reports 40.97% increase in ownership of DUL / Alnylam Pharmaceuticals, Inc.

On May 14, 2026 - Us Bancorp \de\ filed a 13F-HR form disclosing ownership of 7,381 shares of Alnylam Pharmaceuticals, Inc. (DE:DUL) valued at $2,108,752 USD as of March 31, 2026. The entity filed a previous 13F-HR on January 30, 2026 disclosing 5,236 shares of Alnylam Pharmaceuticals, Inc.. This represents a change in shares of 40.97% during the quarter. The current value of the position is $1,858,536 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date		 Effective
Date		Form Security Class ID Avg Price
Paid (Est)		 Reported
Shares		 ΔShares ΔShares
(%)		 Reported
Value
(x1000)		 ΔValue
(%)		 Alloc
(%)		 ΔAlloc ΔAlloc (%) Cost Basis
(x1000)		 Unrealized
Gain/Loss
(x1000)
2026-05-14 2026-03-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 7,381 2,145 40.97 2,442 17.29 0.0009
2026-01-30 2025-12-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 5,236 -410 -7.26 2,082 -19.11 0.0024
2025-11-12 2025-09-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 5,646 946 20.13 2,575 68.02 0.0031
2025-07-24 2025-06-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 4,700 110 2.40 1,533 23.65 0.0019
2025-05-08 2025-03-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 4,590 -192 -4.02 1,239 10.13 0.0017
2025-02-05 2024-12-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 4,782 -796 -14.27 1,125 -26.66 0.0015
2024-10-28 2024-09-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 5,578 -1,516 -21.37 1,534 -10.97 0.0020
2024-08-07 2024-06-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 7,094 534 8.14 1,724 75.82 0.0023
2024-05-08 2024-03-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 6,560 -691 -9.53 980 -29.34 0.0014
2024-02-09 2023-12-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 7,251 -17 -0.23 1,388 7.77 0.0021
2023-11-03 2023-09-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 7,268 -149 -2.01 1,287 -8.59 0.0021
2023-08-10 2023-06-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 7,417 -588 -7.35 1,409 -12.16 0.0023
2023-05-09 2023-03-31 13F ALNYLAM PHARMACEUTICALS COMMON STOCK 02043Q107 8,005 -26 -0.32 1,604 -15.99 0.0027
2023-02-13 2022-12-31 13F ALNYLAM PHARMACEUTICALS COMMON STOCK 02043Q107 8,031 -212 -2.57 1,909 15.64 0.0034
2022-10-27 2022-09-30 13F ALNYLAM PHARMACEUTICALS COMMON STOCK 02043Q107 8,243 197 2.45 1,650 40.55 0.0034
2022-08-01 2022-06-30 13F ALNYLAM PHARMACEUTICALS COMMON STOCK 02043Q107 8,046 -2,232 -21.72 1,174 -30.04 0.0023
2022-05-11 2022-03-31 13F ALNYLAM PHARMACEUTICALS COMMON STOCK 02043Q107 10,278 679 7.07 1,678 3.07 0.0028
2022-02-11 2021-12-31 13F ALNYLAM PHARMACEUTICALS COMMON STOCK 02043Q107 9,599 1,008 11.73 1,628 0.37 0.0026
2021-11-10 2021-09-30 13F ALNYLAM PHARMACEUTICALS COMMON STOCK 02043Q107 8,591 108 1.27 1,622 12.87 0.0031
2021-08-05 2021-06-30 13F ALNYLAM PHARMACEUTICALS COMMON STOCK 02043Q107 8,483 239 2.90 1,437 23.45 0.0027
2021-04-28 2021-03-31 13F ALNYLAM PHARMACEUTICALS COMMON STOCK 02043Q107 8,244 6,186 300.58 1,164 334.33 0.0024
2021-02-04 2020-12-31 13F ALNYLAM PHARMACEUTICALS COMMON STOCK 02043Q107 2,058 824 66.77 268 49.72 0.0006
2020-11-10 2020-09-30 13F ALNYLAM PHARMACEUTICALS COMMON STOCK 02043Q107 1,234 119 10.67 179 8.48 0.0004
2020-08-07 2020-06-30 13F ALNYLAM PHARMACEUTICALS COMMON STOCK 02043Q107 1,115 71 6.80 165 44.74 0.0004
2020-05-13 2020-03-31 13F ALNYLAM PHARMACEUTICALS COMMON STOCK 02043Q107 1,044 -120 -10.31 114 -14.29 0.0004
2020-02-04 2019-12-31 13F ALNYLAM PHARMACEUTICALS COMMON STOCK 02043Q107 1,164 48 4.30 133 49.44 0.0003
2019-11-08 2019-09-30 13F ALNYLAM PHARMACEUTICALS COMMON STOCK 02043Q107 1,116 488 77.71 89 93.48 0.0002
2019-08-13 2019-06-30 13F ALNYLAM PHARMACEUTICALS COMMON STOCK 02043Q107 628 259 70.19 46 31.43 0.0001
2019-05-08 2019-03-31 13F ALNYLAM PHARMACEUTICALS COMMON STOCK 02043Q107 369 147 66.22 35 118.75 0.0001
2019-02-13 2018-12-31 13F ALNYLAM PHARMACEUTICALS COMMON STOCK 02043Q107 222 -76 -25.50 16 -38.46 0.0001
2018-10-31 2018-09-30 13F ALNYLAM PHARMACEUTICALS COMMON STOCK 02043Q107 298 142 91.03 26 73.33 0.0001
2018-08-08 2018-06-30 13F ALNYLAM PHARMACEUTICALS COMMON STOCK 02043Q107 156 -213 -57.72 15 -66.67 0.0000
2018-05-08 2018-03-31 13F ALNYLAM PHARMACEUTICALS COMMON STOCK 02043Q107 369 128 53.11 45 50.00 0.0001
2018-02-02 2017-12-31 13F ALNYLAM PHARMACEUTICALS COMMON STOCK 02043Q107 241 -222 -47.95 30 -45.45 0.0001
2017-11-13 2017-09-30 13F ALNYLAM PHARMACEUTICALS COMMON STOCK 02043Q107 463 393 561.43 55 816.67 0.0002
2017-07-19 2017-06-30 13F ALNYLAM PHARMACEUTICALS COMMON STOCK 02043Q107 70 0 0.00 6 50.00 0.0000
2017-05-03 2017-03-31 13F ALNYLAM PHARMACEUTICALS COMMON STOCK 02043Q107 70 -39 -35.78 4 0.00 0.0000
2017-02-08 2016-12-31 13F ALNYLAM PHARMACEUTICALS COMMON STOCK 02043Q107 109 -478 -81.43 4 -90.00 0.0000
2016-11-04 2016-09-30 13F ALNYLAM PHARMACEUTICALS COMMON STOCK 02043Q107 587 -37 -5.93 40 17.65 0.0001
2016-08-10 2016-06-30 13F ALNYLAM PHARMACEUTICALS COMMON STOCK 02043Q107 624 44 7.59 34 -5.56 0.0001
2016-05-13 2016-03-31 13F ALNYLAM PHARMACEUTICALS COMMON STOCK 02043Q107 580 467 413.27 36 260.00 0.0001
2016-02-10 2015-12-31 13F ALNYLAM PHARMACEUTICALS COMMON STOCK 02043Q107 113 59 109.26 10 150.00 0.0000
2015-11-16 2015-09-30 13F ALNYLAM PHARMACEUTICALS COMMON STOCK 02043Q107 54 -129 -70.49 4 -81.82 0.0000
2015-08-10 2015-06-30 13F ALNYLAM PHARMACEUTICALS COMMON STOCK 02043Q107 183 146 394.59 22 450.00 0.0001
2015-05-08 2015-03-31 13F ALNYLAM PHARMACEUTICALS COMMON STOCK 02043Q107 37 -253 -87.24 4 -85.71 0.0000
2015-02-13 2014-12-31 13F ALNYLAM PHARMACEUTICALS COMMON STOCK 02043Q107 290 -738 -71.79 28 -65.00 0.0001
2014-11-14 2014-09-30 13F ALNYLAM PHARMACEUTICALS COMMON STOCK 02043Q107 1,028 -2,208 -68.23 80 -60.78 0.0003
2014-08-14 2014-06-30 13F ALNYLAM PHARMACEUTICALS COMMON STOCK 02043Q107 3,236 -728 -18.37 204 -23.31 0.0008
2014-05-14 2014-03-31 13F ALNYLAM PHARMACEUTICALS COMMON STOCK 02043Q107 3,964 -147 -3.58 266 0.76 0.0011
2014-02-13 2013-12-31 13F ALNYLAM PHARMACEUTICALS COMMON STOCK 02043Q107 4,111 -549 -11.78 264 -11.41 0.0011
2013-11-07 2013-09-30 13F ALNYLAM PHARMACEUTICALS COMMON STOCK 02043Q107 4,660 2,660 133.00 298 380.65 0.0013
2013-08-09 2013-06-30 13F ALNYLAM PHARMACEUTICALS COMMON STOCK 02043Q107 2,000 2,000 62 0.0003
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.